Trial Profile
A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU® (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Ipsen
- 18 Feb 2014 New source identified and integrated: European Clinical Trials Database record.
- 17 Feb 2014 New trial record